Fecal microbiota transplantation enables the reconstitution of gut bacteria, and has been proven effective to treat Clostridium difficile infections of the colon. But, as you can imagine, the nature of the active ingredient presents a tough drug delivery challenge. Luckily, the field is advancing.
Regulus Therapeutics, at work on a microRNA approach to hepatitis C, watched its shares skyrocket on positive early data for its lead candidate, which significantly reduced viral loads with a single dose.
With several players now in the race toward a vaccine for Ebola, Johnson & Johnson says it is ramping up development efforts toward its own program, devoting $200 million to the cause.
Scientists in Spain have now developed small particles with the ability to encapsulate growth factors when implanted in the brain, which could ultimately reverse the effects of these diseases by spurring the growth of new, healthy neurons.
As the promise of harnessing the immune system to fight cancer grabs headlines around the industry, venture stalwarts Fidelity Biosciences and Atlas Venture have teamed up to launch Unum Therapeutics, a Cambridge, MA, startup with a hybrid approach to the field.
While the testosterone therapy field is under fire from government regulators, Menlo Park, CA-based TesoRx is licensing its oral-testosterone replacement therapy to a subsidiary of South African generics maker Aspen Pharmacare.
Charles River Laboratories has unveiled a new technology it says can better test for impurities by combining two common methods into a single product, making for a flexible solution.
PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.
Blaze Bioscience has nabbed a $1.5 million Small Business Innovation Research (SBIR) Phase II award from the National Cancer Institute (NCI) to continue researching its product, called Tumor Paint BLZ-100, which will be studied in people with soft tissue sarcoma. The company was awarded the funding based on the successful completion of a trial in 27 pet dogs with various tumor types.
It's been a productive couple of weeks for Aratana Therapeutics. I had the opportunity to sit down with Aratana CEO Steven St. Peter last week to chat about recent developments, and more generally, the prospects for the animal health industry going forward. Here are some excerpts from our conversation.